Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors.
Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
[EN] MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES UTILISÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2011100401A1
公开(公告)日:2011-08-18
The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
申请人:Bessis Anne-Sophie
公开号:US20090124625A1
公开(公告)日:2009-05-14
The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
Alkynyl derivatives as modulators of metatropic glutamate receptors
申请人:Addex Pharma SA
公开号:US08101637B2
公开(公告)日:2012-01-24
The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors-subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.